Back to Journals » Substance Abuse and Rehabilitation » Volume 2 » Issue 1

Selective review and commentary on emerging pharmacotherapies for opioid addiction

Authors Ling W, Mooney L, Zhao, Nielsen, Torrington, Miotto K

Published 28 October 2011 Volume 2011:2(1) Pages 181—188

DOI https://doi.org/10.2147/SAR.S22782

Review by Single anonymous peer review

Peer reviewer comments 2



Walter Ling1, Larissa Mooney1, Min Zhao2, Suzanne Nielsen1, Matthew Torrington1, Karen Miotto1
1Integrated Substance Abuse Programs, University of California, Los Angeles, CA, USA; 2Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract: Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians, and regulatory personnel from most concerns about diversion, misuse, and unintended exposure in children. In addition, two recently approved formulations of previously proven medications are in early phases of implementation. The sublingual film form of buprenorphine + naloxone (Suboxone®) provides a less divertible, more quickly administered, more child-proof version than the buprenorphine + naloxone sublingual tablet. The injectable depot form of naltrexone (Vivitrol®) ensures consistent opioid receptor blockade for one month between administrations, removing concerns about medication compliance. The clinical implications of these developments have attracted increasing attention from clinicians and policymakers in the US and around the world, especially given that human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious diseases are recognized as companions to opioid addiction, commanding more efforts to reduce opioid addiction. While research and practice improvement efforts continue, reluctance to adopt new medications and procedures can be expected, especially considerations in the regulatory process and in the course of implementation. Best practices and improved outcomes will ultimately emerge from continued development efforts that reflect input from many quarters.

Keywords:
buprenorphine, naltrexone, probuphine, lofexidine, implant buprenorphine, buprenorphine film

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.